CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
August 14 2008 - 1:15PM
PR Newswire (US)
- Awards recognize innovative biopharmaceutical drugs and devices
that have made a deep impact on the quality of human life - PALO
ALTO, Calif., Aug. 14 /PRNewswire-FirstCall/ -- CV Therapeutics,
Inc. (NASDAQ:CVTX) today announced that its chronic angina therapy
Ranexa(R) (ranolazine extended-releases tablets) has been selected
as a finalist for the prestigious Prix Galien USA 2008 award which
honors the best pharmaceutical agent and best biotechnology product
of the year. Winners will be announced on September 24, 2008 in New
York. "Being named a finalist for the Prix Galien USA awards is a
great honor. We congratulate the dedicated employees, researchers
and physicians who make it possible for this important medicine to
help patients every day," said Louis G. Lange, M.D., Ph.D.,
chairman and chief executive officer of CV Therapeutics. The Prix
Galien USA Awards committee of 11, including seven Nobel Laureates,
recognizes the technical, scientific and clinical research skills
necessary to develop innovative medicines that improve the human
condition, and is considered the industry's highest accolade for
pharmaceutical research and development. About Ranexa(R) In the
United Sates, Ranexa(R) (ranolazine extended-release tablets) is
indicated for the treatment of chronic angina in patients who have
not achieved an adequate response with other antianginal drugs. In
Europe, ranolazine is indicated as add-on therapy for the
symptomatic treatment of patients with stable angina pectoris who
are inadequately controlled or intolerant to first-line antianginal
therapies. About CV Therapeutics CV Therapeutics, Inc.,
headquartered in Palo Alto, California, is a biopharmaceutical
company primarily focused on applying molecular cardiology to the
discovery, development and commercialization of novel, small
molecule drugs for the treatment of cardiovascular diseases. CV
Therapeutics Ltd. is the company's European subsidiary based in the
United Kingdom. CV Therapeutics' approved products in the United
States include Ranexa(R) (ranolazine extended-release tablets),
indicated for the treatment of chronic angina in patients who have
not achieved an adequate response with other antianginal drugs, and
Lexiscan(TM) (regadenoson) injection for use as a pharmacologic
stress agent in radionuclide myocardial perfusion imaging in
patients unable to undergo adequate exercise stress. Ranolazine is
approved for use in the European Union as add-on therapy for the
symptomatic treatment of patients with stable angina pectoris who
are inadequately controlled or intolerant to first-line antianginal
therapies. Except for the historical information contained herein,
the matters set forth in this press release, including statements
as to research and development and commercialization of products,
are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially,
including operating losses and fluctuations in operating results;
capital requirements; regulatory review and approval of our
products; special protocol assessment agreement; the conduct and
timing of clinical trials; commercialization of products; market
acceptance of products; product labeling; concentrated customer
base; reliance on strategic partnerships and collaborations;
uncertainties in drug development; uncertainties regarding
intellectual property and other risks detailed from time to time in
CV Therapeutics' SEC reports, including its Quarterly Report on
Form 10-Q for the quarter ended June 30, 2008. CV Therapeutics
disclaims any intent or obligation to update these forward-looking
statements. DATASOURCE: CV Therapeutics, Inc. CONTACT: Investors
and Media, John Bluth, Executive Director, Corporate Communications
& Investor Relations of CV Therapeutics, Inc., +1-650-384-8850
Web site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024